DAVIS, CA – September 15, 2015 – Marrone Bio Innovations, Inc. (MBI), (NASDAQ: MBII), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, announced today that Congressman John Garamendi visited its headquarters in Davis, CA to host a Manufacturing Advisory Committee and to tour MBI’s facilities, including its lab and greenhouse.

Pam Marrone and Congressman John Garamendi Visits Marrone Bio Innovations FacilitiesPam Marrone, Chief Executive Officer of Marrone Bio Innovations commented, “We were delighted to host Congressman Garamendi and to provide a tour of our facilities, including our new greenhouse which is playing a key role in enabling execution of our research and product development initiatives.  We are committed to developing new effective and environmentally responsible bio-based products that promote plant health and control unwanted pests in agriculture.  We appreciate the Congressman’s ongoing support in helping MBI execute our business strategy.”

About Marrone Bio Innovations

Marrone Bio Innovations, Inc. (NASDAQ: MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.

Forward Looking Statements

Portions of this press release may constitute “forward-looking statements,” and assumptions underlying such forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any such forward-looking statements are made within the “safe-harbor” protections of the PSLRA, should not be relied upon as representing our views as of any subsequent date, and we are under no obligation to, and expressly disclaims any responsibility to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements in this filing include those regarding Grandevo, including its potential uses, availability in the EU and registration with applicable agencies. Such forward-looking statements are based on information available to us as of the date of this release and involve a number of risks and uncertainties, some beyond our control, that could cause actual results to differ materially from those anticipated by these forward-looking statements. Such risks include inability to obtain regulatory approval for or commercialize our products, or to comply with ongoing and changing regulatory requirements, which could delay or prevent sales, failure of customers to adopt our products and competition in the markets for our products. Additional information that could lead to material changes in our performance is contained in our filings with the Securities and Exchange Commission.

 

 

Media Contact:

Cory Ziskind
ICR
646-277-1232
Cory.Ziskind@icrinc.com